secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-132838
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera presents Phase 1 healthy volunteer data for oral STAT6 degrader KT-621
-----------------------------------------------------------------------------

- Hosted conference call on June 2, 2025 to discuss Phase 1 results for KT-621, a first-in-class oral STAT6 degrader.
- Slide presentation furnished as Exhibit 99.1; specific safety, PK/PD, or efficacy data not provided in available text.
- KT-621 targets immuno-inflammatory diseases; Phase 1 study in healthy volunteers completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525132838/0001193125-25-132838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525132838/d943327d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer